carnitine has been researched along with Cirrhosis in 18 studies
Excerpt | Relevance | Reference |
---|---|---|
"Ezetimibe improved hepatic fibrosis but increased hepatic long-chain fatty acids and HbA1c in patients with NAFLD." | 9.19 | The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. ( Arai, K; Honda, M; Kaneko, S; Kato, K; Kita, Y; Misu, H; Mizukoshi, E; Nakamura, M; Ota, T; Sunagozaka, H; Takamura, T; Takeshita, Y; Yamada, K; Yamashita, T; Zen, Y, 2014) |
" Here, we extend our findings and provide evidence of epithelial-mesenchymal transition (EMT)-associated renal fibrosis caused by PFOS and the protection by l-carnitine." | 7.85 | From the Cover: l-Carnitine via PPARγ- and Sirt1-Dependent Mechanisms Attenuates Epithelial-Mesenchymal Transition and Renal Fibrosis Caused by Perfluorooctanesulfonate. ( Chang, CC; Chou, HC; Jin, L; Juan, SH; Lin, CY; Wen, LL, 2017) |
" Simultaneous treatment with L-carnitine attenuated the renal fibrosis (which correlated with a reduction of plasma TGF-β1 levels) and the pro-oxidative and proinflammatory status reported in L-NAME groups, with a concomitant increase in the expression of PPAR-γ." | 7.80 | L-carnitine attenuates the development of kidney fibrosis in hypertensive rats by upregulating PPAR-γ. ( Arévalo, M; Blanca, AJ; Mate, A; Miguel-Carrasco, JL; Ruiz-Armenta, MV; Vázquez, CM; Zambrano, S, 2014) |
"L-carnitine supplementation attenuates cardiac fibrosis by increasing prostacyclin production through arachidonic acid pathway, and may be a promising therapeutic option for HFpEF." | 7.78 | L-Carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease. ( Aizawa, Y; Kamimura, D; Komuro, I; Mano, T; Miwa, T; Ohtani, T; Omori, Y; Sakata, Y; Soga, T; Takeda, Y; Tamaki, S; Tsukamoto, Y; Yamamoto, K, 2012) |
"l-Carnitine (LC) plays an essential role in the β-oxidation of long-chain fatty acids in lipid metabolism." | 5.39 | L-Carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPAR-γ expression. ( Arévalo, M; Blanca, AJ; Mate, A; Miguel-Carrasco, JL; Ruiz-Armenta, MV; Vázquez, CM; Vázquez, MJ; Zambrano, S, 2013) |
"Ezetimibe improved hepatic fibrosis but increased hepatic long-chain fatty acids and HbA1c in patients with NAFLD." | 5.19 | The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. ( Arai, K; Honda, M; Kaneko, S; Kato, K; Kita, Y; Misu, H; Mizukoshi, E; Nakamura, M; Ota, T; Sunagozaka, H; Takamura, T; Takeshita, Y; Yamada, K; Yamashita, T; Zen, Y, 2014) |
" Here, we extend our findings and provide evidence of epithelial-mesenchymal transition (EMT)-associated renal fibrosis caused by PFOS and the protection by l-carnitine." | 3.85 | From the Cover: l-Carnitine via PPARγ- and Sirt1-Dependent Mechanisms Attenuates Epithelial-Mesenchymal Transition and Renal Fibrosis Caused by Perfluorooctanesulfonate. ( Chang, CC; Chou, HC; Jin, L; Juan, SH; Lin, CY; Wen, LL, 2017) |
" The aim of the study was to investigate the role of MMPs and their inhibitors (TIMPs), in the pathogenesis of choline deficiency-induced cardiomyopathy, and the way they are affected by carnitine supplementation." | 3.83 | Immunohistochemical determination of the extracellular matrix modulation in a rat model of choline-deprived myocardium: the effects of carnitine. ( Giannopoulou, I; Karkalousos, P; Kriebardis, A; Lazaris, A; Liapi, C; Panayiotides, I; Papavdi, A; Perelas, A; Strilakou, A, 2016) |
" Simultaneous treatment with L-carnitine attenuated the renal fibrosis (which correlated with a reduction of plasma TGF-β1 levels) and the pro-oxidative and proinflammatory status reported in L-NAME groups, with a concomitant increase in the expression of PPAR-γ." | 3.80 | L-carnitine attenuates the development of kidney fibrosis in hypertensive rats by upregulating PPAR-γ. ( Arévalo, M; Blanca, AJ; Mate, A; Miguel-Carrasco, JL; Ruiz-Armenta, MV; Vázquez, CM; Zambrano, S, 2014) |
"L-carnitine supplementation attenuates cardiac fibrosis by increasing prostacyclin production through arachidonic acid pathway, and may be a promising therapeutic option for HFpEF." | 3.78 | L-Carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease. ( Aizawa, Y; Kamimura, D; Komuro, I; Mano, T; Miwa, T; Ohtani, T; Omori, Y; Sakata, Y; Soga, T; Takeda, Y; Tamaki, S; Tsukamoto, Y; Yamamoto, K, 2012) |
"Liver fibrosis was apparent at 20 days and 13 weeks." | 1.48 | Maternal L-carnitine supplementation improves glucose and lipid profiles in female offspring of dams exposed to cigarette smoke. ( Al-Odat, I; Chan, YL; Chen, H; McGrath, KC; Oliver, BG; Pollock, CA; Saad, S, 2018) |
"The study investigates the effects of choline deficiency on myocardial performance in adult rats and the possible modifications after carnitine administration." | 1.39 | Heart dysfunction induced by choline-deficiency in adult rats: the protective role of L-carnitine. ( Douzis, ICh; Karkalousos, PL; Lazaris, AC; Liapi, CA; Mourouzis, IS; Pantos, CI; Perelas, AI; Strilakou, AA; Stylianaki, AT, 2013) |
"l-Carnitine (LC) plays an essential role in the β-oxidation of long-chain fatty acids in lipid metabolism." | 1.39 | L-Carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPAR-γ expression. ( Arévalo, M; Blanca, AJ; Mate, A; Miguel-Carrasco, JL; Ruiz-Armenta, MV; Vázquez, CM; Vázquez, MJ; Zambrano, S, 2013) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (5.56) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (11.11) | 29.6817 |
2010's | 11 (61.11) | 24.3611 |
2020's | 4 (22.22) | 2.80 |
Authors | Studies |
---|---|
Emran, T | 1 |
Chowdhury, NI | 1 |
Sarker, M | 1 |
Bepari, AK | 1 |
Hossain, M | 1 |
Rahman, GMS | 1 |
Reza, HM | 1 |
Ottria, A | 1 |
Hoekstra, AT | 1 |
Zimmermann, M | 1 |
van der Kroef, M | 1 |
Vazirpanah, N | 1 |
Cossu, M | 1 |
Chouri, E | 1 |
Rossato, M | 1 |
Beretta, L | 1 |
Tieland, RG | 1 |
Wichers, CGK | 1 |
Stigter, E | 1 |
Gulersonmez, C | 1 |
Bonte-Mineur, F | 1 |
Berkers, CR | 1 |
Radstake, TRDJ | 1 |
Marut, W | 1 |
Zhao, HY | 1 |
Li, HY | 1 |
Jin, J | 1 |
Jin, JZ | 1 |
Zhang, LY | 1 |
Xuan, MY | 1 |
Jin, XM | 1 |
Jiang, YJ | 1 |
Zheng, HL | 1 |
Jin, YS | 1 |
Jin, YJ | 1 |
Choi, BS | 1 |
Yang, CW | 1 |
Piao, SG | 1 |
Li, C | 1 |
Chen, YC | 1 |
Cheng, CY | 1 |
Liu, CT | 1 |
Sue, YM | 1 |
Chen, TH | 1 |
Hsu, YH | 1 |
Huang, NJ | 1 |
Chen, CH | 1 |
Chou, HC | 1 |
Wen, LL | 1 |
Chang, CC | 1 |
Lin, CY | 1 |
Jin, L | 1 |
Juan, SH | 1 |
Saad, S | 1 |
Al-Odat, I | 1 |
Chan, YL | 1 |
McGrath, KC | 1 |
Pollock, CA | 1 |
Oliver, BG | 1 |
Chen, H | 2 |
Chen, DQ | 1 |
Cao, G | 1 |
Argyopoulos, CP | 1 |
Yu, H | 1 |
Su, W | 1 |
Chen, L | 1 |
Samuels, DC | 1 |
Zhuang, S | 1 |
Bayliss, GP | 1 |
Zhao, S | 1 |
Yu, XY | 1 |
Vaziri, ND | 1 |
Wang, M | 1 |
Liu, D | 1 |
Mao, JR | 1 |
Ma, SX | 1 |
Zhao, J | 1 |
Zhang, Y | 1 |
Shang, YQ | 1 |
Kang, H | 1 |
Ye, F | 1 |
Cheng, XH | 1 |
Li, XR | 1 |
Zhang, L | 1 |
Meng, MX | 1 |
Guo, Y | 1 |
Zhao, YY | 1 |
Strilakou, AA | 1 |
Lazaris, AC | 1 |
Perelas, AI | 1 |
Mourouzis, IS | 1 |
Douzis, ICh | 1 |
Karkalousos, PL | 1 |
Stylianaki, AT | 1 |
Pantos, CI | 1 |
Liapi, CA | 1 |
Takeshita, Y | 1 |
Takamura, T | 1 |
Honda, M | 1 |
Kita, Y | 1 |
Zen, Y | 1 |
Kato, K | 1 |
Misu, H | 1 |
Ota, T | 1 |
Nakamura, M | 1 |
Yamada, K | 1 |
Sunagozaka, H | 1 |
Arai, K | 1 |
Yamashita, T | 2 |
Mizukoshi, E | 1 |
Kaneko, S | 1 |
Zambrano, S | 2 |
Blanca, AJ | 2 |
Ruiz-Armenta, MV | 2 |
Miguel-Carrasco, JL | 2 |
Arévalo, M | 2 |
Mate, A | 2 |
Vázquez, CM | 2 |
Nishikawa, H | 1 |
Osaki, Y | 1 |
Strilakou, A | 1 |
Perelas, A | 1 |
Lazaris, A | 1 |
Papavdi, A | 1 |
Karkalousos, P | 1 |
Giannopoulou, I | 1 |
Kriebardis, A | 1 |
Panayiotides, I | 1 |
Liapi, C | 1 |
Kolwicz, SC | 1 |
Olson, DP | 1 |
Marney, LC | 1 |
Garcia-Menendez, L | 1 |
Synovec, RE | 1 |
Tian, R | 1 |
Omori, Y | 1 |
Ohtani, T | 1 |
Sakata, Y | 1 |
Mano, T | 1 |
Takeda, Y | 1 |
Tamaki, S | 1 |
Tsukamoto, Y | 1 |
Kamimura, D | 1 |
Aizawa, Y | 1 |
Miwa, T | 1 |
Komuro, I | 1 |
Soga, T | 1 |
Yamamoto, K | 1 |
Vázquez, MJ | 1 |
Kao, HJ | 1 |
Cheng, CF | 1 |
Chen, YH | 1 |
Hung, SI | 1 |
Huang, CC | 1 |
Millington, D | 1 |
Kikuchi, T | 1 |
Wu, JY | 1 |
Chen, YT | 1 |
Shirazi, M | 1 |
Noorafshan, A | 1 |
Kroup, M | 1 |
Tanideh, N | 1 |
Kobayashi, A | 1 |
Yamazaki, N | 1 |
Miura, K | 1 |
Shirasawa, H | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease[NCT05719714] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 review available for carnitine and Cirrhosis
Article | Year |
---|---|
Liver Cirrhosis: Evaluation, Nutritional Status, and Prognosis.
Topics: Carcinoma, Hepatocellular; Carnitine; Electric Impedance; Fibrosis; Hand Strength; Hepatitis C, Chro | 2015 |
1 trial available for carnitine and Cirrhosis
Article | Year |
---|---|
The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial.
Topics: Aged; Anticholesteremic Agents; Area Under Curve; Azetidines; Biopsy; Carnitine; Cholesterol; Ezetim | 2014 |
16 other studies available for carnitine and Cirrhosis
Article | Year |
---|---|
L-carnitine protects cardiac damage by reducing oxidative stress and inflammatory response via inhibition of tumor necrosis factor-alpha and interleukin-1beta against isoproterenol-induced myocardial infarction.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Carnitine; Disease Models, Animal; Fibrosis; Inflam | 2021 |
Fatty Acid and Carnitine Metabolism Are Dysregulated in Systemic Sclerosis Patients.
Topics: Adult; Aged; Carnitine; Cohort Studies; Cytokines; Dendritic Cells; Etoposide; Fatty Acids; Female; | 2020 |
L-carnitine treatment attenuates renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction.
Topics: Animals; Carnitine; Fibrosis; Hydrogen Peroxide; Kidney; Phosphatidylinositol 3-Kinases; Rats; Rats, | 2021 |
Combined protective effects of oligo-fucoidan, fucoxanthin, and L-carnitine on the kidneys of chronic kidney disease mice.
Topics: Animals; Apoptosis; Biomarkers; Carnitine; Cell Line; Disease Models, Animal; Drug Therapy, Combinat | 2021 |
From the Cover: l-Carnitine via PPARγ- and Sirt1-Dependent Mechanisms Attenuates Epithelial-Mesenchymal Transition and Renal Fibrosis Caused by Perfluorooctanesulfonate.
Topics: Acetylation; Alkanesulfonic Acids; Animals; Carnitine; Cell Line; Cell Movement; Cytoprotection; Dis | 2017 |
Maternal L-carnitine supplementation improves glucose and lipid profiles in female offspring of dams exposed to cigarette smoke.
Topics: Animals; Biomarkers; Carnitine; Cigarette Smoking; Dietary Supplements; Female; Fibrosis; Glucose; L | 2018 |
Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan.
Topics: Acetylcarnitine; Animals; Canavanine; Carnitine; Case-Control Studies; Disease Models, Animal; Disea | 2019 |
Heart dysfunction induced by choline-deficiency in adult rats: the protective role of L-carnitine.
Topics: Animals; Cardiotonic Agents; Carnitine; Choline Deficiency; Dietary Supplements; Edema, Cardiac; Fib | 2013 |
L-carnitine attenuates the development of kidney fibrosis in hypertensive rats by upregulating PPAR-γ.
Topics: Animals; Carnitine; Cells, Cultured; Collagen; Connective Tissue Growth Factor; Cytoprotection; Dise | 2014 |
Immunohistochemical determination of the extracellular matrix modulation in a rat model of choline-deprived myocardium: the effects of carnitine.
Topics: Administration, Oral; Animals; Cardiomyopathies; Carnitine; Choline Deficiency; Disease Models, Anim | 2016 |
Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy.
Topics: Acetyl-CoA Carboxylase; Animals; Aorta; Blotting, Western; Cardiomegaly; Carnitine; Constriction, Pa | 2012 |
L-Carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease.
Topics: Aged; Animals; Carnitine; Delta-5 Fatty Acid Desaturase; Electrophoresis, Capillary; Epoprostenol; F | 2012 |
L-Carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPAR-γ expression.
Topics: Animals; Antihypertensive Agents; Carnitine; Collagen Type I; Collagen Type II; Connective Tissue Gr | 2013 |
ENU mutagenesis identifies mice with cardiac fibrosis and hepatic steatosis caused by a mutation in the mitochondrial trifunctional protein beta-subunit.
Topics: Adipose Tissue; Animals; Base Sequence; Blotting, Western; Carnitine; Chromosome Mapping; Ethylnitro | 2006 |
Comparison of the effects of captopril, tamoxifen and L-carnitine on renal structure and fibrosis after total unilateral ureteral obstruction in the rat.
Topics: Animals; Captopril; Carnitine; Female; Fibrosis; Kidney; Rats; Rats, Sprague-Dawley; Tamoxifen; Uret | 2007 |
Effects of L-carnitine and verapamil on myocardial carnitine concentration and histopathology of Syrian hamster BIO 14.6.
Topics: Animals; Calcinosis; Cardiomyopathies; Carnitine; Cricetinae; Fibrosis; Mesocricetus; Myocardium; Ne | 1986 |